Despite the recognized financial investments and risks for pharmaceutical companies, clinical trials (CTs) remain the gold standard for developing safe medications. The integration of artificial intelligence (AI) is being explored to enhance drug development through the analysis of vast clinical and molecular data. AI models are necessary for extracting actionable insights, expediting drug research, and improving patient recruitment and monitoring. Preclinical research, essential for assessing the safety and efficacy of new treatments, involves both in vitro and in vivo investigations focused on pharmacodynamics, pharmacokinetics, and toxicology. This phase aims to establish safe starting doses for human trials and must adhere to strict ethical standards before regulatory approval allows clinical studies to commence.